AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

EDEN RESEARCH PLC

Regulatory Filings Apr 25, 2013

7615_rns_2013-04-25_2087c94a-6b8d-4790-82ff-34ebc973e883.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1627D

Eden Research plc

25 April 2013

Eden Research Plc

("Eden" or "Company")

Notice of Allowance from ARIPO for Plant Bacteria Fungi Formulae

Eden Research plc (AIM: EDEN), the AIM listed agrochemical and encapsulation development company, announces that the African Regional Intellectual Property Organisation (ARIPO) has issued a Notice of Allowance for Plant Bacteria Fungi Formulae (number 004525) to the Company.

This notice relates to formulations of more than one terpene selected from a group of four terpenes. Specific formulations within this definition have proven to be particularly effective for controlling fungal and bacterial plant pathogens.

The ARIPO designated states for this application are the following: Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

Clive Newitt, Managing Director of Eden comments: "We are delighted to announce this Notice of Allowance for Plant Bacteria Fungi Formulae which helps continue to strengthen our intellectual property portfolio. It also helps Eden to further establish its presence in Africa, which is becoming an increasingly significant market in the worldwide food and crop production sector.

Gaining additional patent coverage in the ARIPO region allows our existing, as well as potential, licensees to commercialise products with the protection that a patent provides from competitive threats and ensure that Eden's unique technologies and products can become a viable and valuable part of the industry.

A large amount of the food and other crops (such as cut flowers) produced in Africa are exported to the European supermarkets which means that it is an important market for Eden in which to establish its presence, as it will assist Eden in its endeavours in ensuring that the food we eat has been treated with effective, environmentally-friendly agrochemicals, such as ours."

Enquiries:

Eden Research plc www.edenresearch.com
Clive Newitt, Managing Director Tel: 01993 862 761
Alex Abrey, Chief Financial Officer
W H Ireland Limited www.wh-ireland.co.uk
John Wakefield Tel: 0117 945 3471
Walbrook PR Ltd Tel: 020 7933 8780; [email protected]
Paul McManus (Media Relations) Mob: 07980 541 893 or [email protected]
Paul Cornelius (Investor Relations) Mob: 07827 879 496 or [email protected]

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDMGZDKDMGFZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.